Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

European Urology, Supplements

Volumn 8, Issue 12, 2009, Pages 852-856

  Schulman, Claude C ^a  

^a FREE UNIVERSITY OF BRUSSELS   (Belgium)

Author keywords

Clinical practice; Intermittent hormone therapy; Prostate cancer; Quality of life; Review article; Side effects; Survival

Indexed keywords

BICALUTAMIDE; CYPROTERONE ACETATE; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN;

CANCER HORMONE THERAPY; CARDIOVASCULAR SYMPTOM; CASTRATION; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DRUG INTERMITTENT THERAPY; HUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; SWEDEN;

EID: 71149103029     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2009.07.005     Document Type: Review

References (26)

1. Heidenreich A., Aus G., Bolla M., et al. EAU guidelines on prostate cancer. Eur Urol 53 (2008) 68-80
2. Lu-Yao G.L., Albertsen P.C., Moore D.F., et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 300 (2008) 173-181
3. Tunn U. Can intermittent hormone therapy fulfil its promise?. Eur Urol Suppl 7 (2008) 752-757
4. Gomella L.G. Contemporary use of hormonal therapy in prostate cancer: managing complications and addressing quality-of-life issues. BJU Int 99 Suppl 1 (2007) 25-29
5. D'Amico A.V., Denham J.W., Crook J., et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 25 (2007) 2420-2425
6. Saigal C.S., Gore J.L., Krupski T.L., Hanley J., Schonlau M., and Litwin M.S. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 110 (2007) 1493-1500
7. Smith M.R., Lee H., and Nathan D.M. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 91 (2006) 1305-1308
8. Braga-Basaria M., Dobs A.S., Muller D.C., et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 24 (2006) 3979-3983
9. Akakura K., Bruchovsky N., Goldenberg S.L., Rennie P.S., Buckley A.R., and Sullivan L.D. Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen. Cancer 71 (1993) 2782-2790
10. Bruchovsky N., Rennie P.S., Coldman A.J., Goldenberg S.L., To M., and Lawson D. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 50 (1990) 2275-2282
11. Rennie P.S., Bruchovsky N., Akakura K., et al. Effect of tumour progression on the androgenic regulation of the androgen receptor. TRPM-2 and YPT1 genes in the Shionogi carcinoma. J Steroid Biochem Mol Biol 50 (1994) 31-40
12. Bruchovsky N., Goldenberg S.L., Akakura K., and Rennie P.S. Luteinizing hormone-releasing hormone agonists in prostate cancer. Elimination of flare reaction by pretreatment with cyproterone acetate and low-dose diethylstilbestrol. Cancer 72 (1993) 1685-1691
13. Gleave M.E., Goldenberg S.L., Jones E.C., Bruchovsky N., and Sullivan L.D. Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer. J Urol 155 (1996) 213-219
14. Eggener S.E., Stern J.A., Jain P.M., et al. Enhancement of intermittent androgen ablation by "off-cycle" maintenance with finasteride in LNCaP prostate cancer xenograft model. Prostate 66 (2006) 495-502
15. Tunn U. The current status of intermittent androgen deprivation (IAD) therapy for prostate cancer: putting IAD under the spotlight. BJU Int 99 Suppl 1 (2007) 19-22
16. Gleave M., Klotz L., and Taneja S.S. The continued debate: intermittent vs. continuous hormonal ablation for metastatic prostate cancer. Urol Oncol 27 (2009) 81-86
17. Boccon-Gibod L., Hammerer P., Madersbacher S., Mottet N., Prayer-Galetti T., and Tunn U. The role of intermittent androgen deprivation in prostate cancer. BJU Int 100 (2007) 738-743
18. Shaw G.L., Wilson P., Cuzick J., et al. International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a meta-analysis of 1446 patients. BJU Int 99 (2007) 1056-1065
19. Calais da Silva F.E.C., Bono A.V., Whelan P., et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol 55 (2009) 1269-1277
20. Hussain M., Tangen C.M., Higano C., et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 24 (2006) 3984-3990
21. Tunn U., Kurek R., Kienle E., and Maubach L. Intermittent is as effective as continuous androgen deprivation in patients with PSA-relapse after radical prostatectomy (RP) [abstract 1458]. J Urol 171 (2004) 384
22. Tunn U.W., Canepa G., Hillger H., and Fuchs W. Intermittent androgen deprivation in patients with PSA-relapse after radical prostatectomy-final results of a European randomized prospective phase-III clinical trial AUO study AP 06/95, EC 507 [abstract 600]. J Urol 177 (2007) 201
23. Calais da Silva F.E., Goncalves F., Santos A., et al. Evaluation of quality of life, side effects and duration of therapy in a phase 3 study of intermittent monotherapy versus continuous combined androgen deprivation [abstract 540]. Eur Urol Suppl 7 (2007) 205
24. Shaw G., and Oliver R.T.D. Intermittent hormone therapy and its place in the contemporary endocrine treatment of prostate cancer. Surg Oncol 18 (2009) 275-282
25. Salonen A.J., Viitanen J., Lundstedt S., Ala-Opas M., Taari K., and Tammela T.L. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation. J Urol 180 (2008) 915-919
26. Wright A.S., Douglas R.C., Thomas L.N., Lazier C.B., and Rittmaster R.S. Androgen-induced regrowth in the castrated rat ventral prostate: role of 5a-reductase. Endocrinology 140 (1999) 4509-4515